Design of Cyclic Peptides

Peptide and Protein Design for Biopharmaceutical Applications

Volumn , Issue , 2009, Pages 133-176

  Demmer, Oliver ^a   Frank, Andreas O ^a   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Conformational influence of cyclization on druglike properties; Cyclic peptide design; Cyclic peptide structures; Cyclic peptides as drug candidates; Cyclic peptides of medicinal interest; Dunitz Waser concept; High throughput screening (HTS) assays; Hydrogen bond networks encountered in cyclic peptides; Peptide cyclization and peptide bond mimetics; Peptides as potential drug molecules

Indexed keywords

EID: 84890588610     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470749708.ch4     Document Type: Chapter

References (171)

1. H.-J. Bö hm, In: H.-J. Böhm and G. Schneider, Protein-Ligand Interactions, 2005, 3-20.
2. P. A. Bartlett and M. Entzeroth, Exploiting Chemical Diversity in Drug Discovery, RSC Publishing, Cambridge, 2006.
3. R. Flaumenhaft, In: J. B. Taylor and D. J. Triggle, Chemical Biology in Comprehensive Medicinal Chemistry, Elsevier, 2007, 129-149.
4. H. Kessler, Peptide Conformations. 19. Conformation and biological-activity of cyclic-peptides, Angewandte Chemie - International Edition, 21, 512-523 (1982).
5. V. J. Hruby, Conformational restrictions of biologically-active peptides via aminoacid side-chain groups, Life Sciences, 31, 189-199 (1982).
6. A. Meyer, J. Auernheimer, A. Modlinger and H. Kessler, Targeting RGO recognizing integrins: drug development, biomaterial research, tumor imaging and targeting, Current Pharmaceutical Design, 12, 2723-2747.
7. H. Weisshoff, T. Wieprecht, P. Henklein, C. Antz and C. Mugge, Cyclic cholecystokinin- analog pentapeptide cyclo (Asp-Trp-Met-Asp-Phe) - an unexpected solution conformation, Biochemical and Biophysical Research Communications, 213, 506- 512 (1995).
8. G. V. Nikiforovich, K. E. Kover, W. J. Zhang and G. R. Marshall, Cyclopentapeptides as flexible conformational templates, Journal of the American Chemical Society, 122, 3262-3273 (2000).
9. R. Haubner et al., Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists, Journal of the American Chemical Society, 118, 7461-7472 (1996).
10. Rodriguez A. M. et al., Characteristics of Ramachandran maps of L-alanine diamides as computed by various molecular mechanics, semiempirical and ab initio MO methods. A search for primary standard of peptide conformational stability, Journal of Molecular Structure: THEOCHEM, 455, 275-301 (1998).
11. R. Schwyzer and U. Ludescher, Homodetic cyclic polypeptides. XIV. Conformation of the cyclic hexapeptides cyclo-glycyl-L-prolylglycylglycyl-L-prolylglycyl by proton magnetic resonance studies and parallel to the cyclodecapeptide gramicidin S, Helvetica Chimica Acta 52, 2033-2040 (1969).
12. M. Aumailley et al., Arg-Gly-Asp constrained within cyclic pentapeptides - strong and selective inhibitors of cell-adhesion to vitronectin and laminin fragment-P1, FEBS Letters, 291, 50-54 (1991).
13. J. Rizo and L. M. Gierasch, Constrained peptides: Models of bioactive peptides and protein substructures, Annual Review of Biochemistry, 61, 387-418 (1992).
14. C. Ramakrishnan, P. K. C. Paul and K. Ramnarayan Cyclic-peptides - Small and big and their conformational aspects, Journal of Biosciences, 8, 239-251 (1985).
15. V. J. Hruby, F. Alobeidi and W. Kazmierski, Emerging approaches in the molecular design of receptor-selective peptide ligands - Conformational, topographical and dynamic considerations, Biochemical Journal, 268, 249-262 (1990).
16. G. F. Gause, M. G. Brazhnikova and N. P. Lissovskaya, Preparation and properties of crystalline gramicidine C, Comptes Rendus De L Academie Des Sciences De L Urss, 43, 217-219 (1944).
17. G. F. Gause and M. G. Brazhnikova, Gramicidin sand - Its use in the treatment of infected wounds, Nature, 154, 703 (1944).
18. G. F. Gause and M. G. Brazhnikova, Gramicin S - Origin and mode of action, Lancet, 2, 715-716 (1944).
19. J. N. Porter, R. Broschard, G. Krupka, P. Little and J. S. Zellat, Isolation and production of polymyxin, Annals of the New York Academy of Sciences, 51, 857-865 (1949).
20. R. G. Shepherd et al., Chemical studies on polymyxin. 1. Isolation and preliminary purification, Journal of the American Chemical Society, 70, 3771-3774 (1948).
21. P. G. Stansly and M. E. Schlosser, Studies on polymyxin - isolation and identification of bacillus-polymyxa and differentiation of polymyxin from certain known antibiotics, Journal of Bacteriology, 54, 549-556 (1947).
22. A. Ruegger et al., Cyclosporin-a, a peptide metabolite from trichoderma-polysporum (link ex pers) rifai, with a remarkable immunosuppressive activity, Helvetica Chimica Acta, 59, 1075-1092 (1976).
23. S. W. Fesik et al., NMR-studies of [U-13C] cyclosporin A bound to cyclophilin - Bound conformation and portions of cyclosporine in binding, Biochemistry, 30, 6574-6583 (1991).
24. J. Klages, C. Neubauer, M. Coles, H. Kessler and B. Luy, Structure refinement of cyclosporin a in chloroform by using RDCs measured in a stretched PDMS-gel, Chembiochem, 6, 1672-1678 (2005).
25. H. R. Loosli et al., Peptide conformations. Part 31. The conformation of cyclosporine A in the crystal and in solution, Helvetica Chimica Acta, 68, 682-704 (1985).
26. A. Sehgal, Peptides 2006 - New Applications in Discovery, Manufacturing, and Therapeutics, D&MD Publications, Westborough, 2006.
27. E. Emanuele, M. Arra and S. Pesenti, Vasopressin and oxytocin as neurohormonal mediators ofMDMA (ecstasy) sociosexual behavioural effects, Medical Hypotheses, 67, 1250-1251 (2006).
28. J. F. Mohr and B. E. Murray, Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus, Clinical Infectious Diseases, 44, 1536-1542 (2007).
29. S. Bellary and A. H. Barnett, Inhaled insulin: new technology, new possibilities, International Journal of Clinical Practice, 60, 728-734 (2006).
30. M. P. Curran and G. M. Keating, Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention, Drugs, 65, 2009-2035 (2005).
31. W. Bauer et al., Sms 201-995 - A very potent and selective octapeptide analog of somatostatin with prolonged action, Life Sciences, 31, 1133-1140 (1982).
32. Y. S. Lee et al., Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors, Journal of Medicinal Chemistry, 50, 5528-5532 (2007).
33. P. W. Schiller, In: C. G. Wermuth, N. Koga, H. Kö nig and B. W. Metcalf, Medicinal Chemistry for the 21st Century, Blackwell Scientific Publications, London, 1992, 215-232.
34. I. Berezowska, N. N. Chung, C. Lemieux, B. C. Wilkes and P. W. Schiller, Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)- Cys]NH2 retain high opioid activity, Journal of Medicinal Chemistry, 50, 1414-1417 (2007).
35. M. E. Hadley and C. Haskell-Luevano, The proopiomelanocortin system, Cutaneous Neuroimmunomodulation: The Proopiomelanocortin System, 885, 1-21 (1999).
36. D. J. Craik, S. Simonsen and N. L. Daly, The cyclotides: novel macrocyclic peptides as scaffolds in drug design, Current Opinion in Drug Discovery & Development, 5, 251-260 (2002).
37. D. J. Craik, Chemistry - Seamless proteins tie up their loose ends, Science, 311, 1563-1564 (2006).
38. R. H.Kimura, A. T. Tran and J. A. Camarero, Biosynthesis of the cyclotide Kalata B1 by using protein splicing, Angewandte Chemie - International Edition, 45, 973-976 (2006).
39. I. Rubio-Aliaga and H. Daniel, Mammalian peptide transporters as targets for drug delivery, Trends in Pharmacological Sciences, 23, 434-440 (2002).
40. N. J. P. Dubree et al., Selective alpha 4 beta 7 integrin antagonists and their potential as antiinflammatory agents, Journal of Medicinal Chemistry, 45, 3451-3457 (2002).
41. R. H. Li, R. H. Hoess, J. S. Bennett and W. F. DeGrado, Use of phage display to probe the evolution of binding specificity and affinity in integrins, Protein Engineering, 16, 65-72 (2003).
42. C. Gilon, C. Mang, E. Lohof, A. Friedler and H. Kessler, In: M. Goodman, A. Felix, L. Moroder and C. Toniolo, Houben-Weyl: Methods of Organic Chemistry, Thieme Verlag, Stuttgart, 2003, 461-542.
43. C. Gilon, D. Halle, M. Chorev, Z. Selinger and G. Byk, Backbone cyclization - A new method for conferring conformational constraint on peptides, Biopolymers, 31, 745- 750 (1991).
44. R. C. D. Milton, S. C. F. Milton and S. B. H. Kent, Total chemical synthesis of a Denzyme - The enantiomers of HIV-1 protease show demonstration of reciprocal chiral substrate-specificity, Science, 256, 1445-1448 (1992).
45. M. Chorev and M. Goodman, Recent developments in retro peptides and proteins - An ongoing topochemical exploration, Trends in Biotechnology, 13, 438-445 (1995).
46. S. Lande, Retrobradykinin - peptide with reverse sequence of bradykinin, Journal of Organic Chemistry, 27, 4558-4562 (1962).
47. J. Rudinger, In: E.J. Ariëns, Drug Design, Academic Press, 1971, 319-649.
48. H. Gerlach, J. A. Owtschinnikow and V. Prelog, Cycloenantiomerie + cyclodiastereomerie. 2. Mitteilung uber cycloenantiomere cyclo-hexaalanyle + ein cycloenantiomeres cyclo-diglycyl-tetraalanyl, Helvetica Chimica Acta, 47, 2294-2301 (1964).
49. H. Gerlach, G. Haas and V. Prelog, Uber zwei cycloisomere triglycyl-Tri-L-alanyle, Helvetica Chimica Acta, 49, 603-607 (1966).
50. V. Prelog and H. Gerlach, Cycloenantiomerie and cyclodiastereomerie. 1. Mitteilung, Helvetica Chimica Acta, 47, 2288-2294 (1964).
51. M. M. Shemyakin, Y. A. Ovchinnikov and V. T. Ivanov, Topochemical investigations on peptide systems, Angewandte Chemie - International Edition, 8, 492-499 (1969).
52. H. Kessler et al., Alanine containing analogs of cyclo(-D-Pro-Phe-Thr-Lys(Z)-Trp- Phe-) - Conformationally controlled structure-activity-relationships, Tetrahedron, 44, 745-759 (1988).
53. D. Heckmann et al., Probing integrin selectivity: Rational design of highly active and selective ligands for the alpha 5 beta 1 and alpha v beta 3 integrin receptor, Angewandte Chemie - International Edition, 46, 3571-3574 (2007).
54. D. Ron et al., N-methylated analogs of Ac[Nle28,31]Cck(26-33) - Synthesis, activity, and receptor selectivity, Journal of Medicinal Chemistry, 35, 2806-2811 (1992).
55. C. Gilon, M. A. Dechantsreiter, F. Burkhart, A. Friedler and H. Kessler, In: M. Goodmann, A. Felix, L. Moroder and C. Toniolo, Houben-Weyl: Methods of Organic Chemistry, Thieme Verlag, Stuttgart, New York, 2003, 215-271.
56. J. Chatterjee et al., Multiple N-methylation by a designed approach enhances receptor selectivity, Journal of Medicinal Chemistry, 50, 5878-5881 (2007).
57. E. Biron, J. Chatterjee and H. Kessler, Optimized selective N-methylation of peptides on solid support, Journal of Peptide Science, 12, 213-219 (2006).
58. E. Biron et al., Improved oral bioavailability of peptides via N-methylation: Somatostatin analogs, Angewandte Chemie - International Edition, 47, 2595- 2599 (2008).
59. J. Gante, H. Kessler, and C. Gibson, In: M. Goodmann, A. Felix, L. Moroder and C. Toniolo, Houben-Weyl: Methods of Organic Chemistry, Thieme Verlag, Stuttgart, 2003, 311-323.
60. H. Kessler, Peptoids - A new approach to the development of pharmaceuticals, Angewandte Chemie - International Edition, 32, 543-544 (1993).
61. H. Weisshoff et al., Novel disulfide-constrained pentapeptides as models for beta-via turns in proteins, FEBS Letters, 372, 203-209 (1995).
62. A. Ravi and P. Balaram, Cyclic peptide disulfides - consecutive beta-turn conformation of a synthetic model peptide corresponding to the active-site of thioredoxin, Biochimica Et Biophysica Acta, 745, 301-309 (1983).
63. M. Hata and G. R. Marshall, Do benzodiazepines mimic reverse-turn structures?, Journal of Computer-aided Molecular Design, 20, 321-331 (2006).
64. O. Demmer, I. Dijkgraaf, M. Schottelius, H. J. Wester and H. Kessler, Introduction of functional groups into peptides via N-alkylation, Organic Letters, 10, 2015-2018 (2008).
65. J. S. Davis, In: J. Jones, A Specialist Periodical Report: Amino Acids, Peptides and Proteins, The Royal Society of Chemistry, Cambridge, 1968-1998.
66. D. J. Faulkner, Marine natural-products, Natural Product Reports, 9, 323-364 (1992).
67. Y. A. Ovchinnikov and V. T. Ivanov, In: H. Neurth and R. L. Hill, The Cyclic Peptides: Structure, Conformation and Function, Academic Press, New York, 1982, 307.
68. J. W. Payne, N. J. Marshall, B. M. Grail and S. Gupta, Conformer profiles and biological activities of peptides, Current Organic Chemistry, 6, 1221-1246 (2002).
69. T. Arndt, U. Arndt, U. Reuning and H. Kessler, In: G. F. Weber, Cancer Therapy: Molecular Targets in Tumor-Host Interactions, Horizon Bioscience, Norfolk, 2005, 93-141.
70. V. J. Hruby, Designing peptide receptor agonists and antagonists, Nature Reviews Drug Discovery, 1, 847-858 (2002).
71. L. H. M. Janssen, Conformational flexibility and receptor interaction, Bioorganic& Medicinal Chemistry, 6, 785-788 (1998).
72. K. D. Kopple et al., Conformational mobility in cyclic oligopeptides, Biopolymers, 33, 1093-1099 (1993).
73. H. Kessler, Detection of intramolecular mobility by NMR spectroscopy. 13. Detection of hindered rotation and inversion by NMR spectroscopy, Angewandte Chemie - International Edition, 9, 219-235 (1970).
74. R. Haubner, D. Finsinger and H. Kessler, Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alpha(v)beta(3) integrin for a new cancer therapy, Angewandte Chemie - International Edition, 36, 1375-1389 (1997).
75. R. W. Hoffmann, Flexible molecules with defined shape - Conformational design, Angewandte Chemie - International Edition, 31, 1124-1134 (1992).
76. G. Fischer, Chemical aspects of peptide bond isomerisation, Chemical Society Reviews, 29, 119-127 (2000).
77. L. M. Gierasch, C. M. Deber, V. Madison, C. H. Niu and E. R. Blout, Cyclicpeptides - Conformations of (X-L-Pro-Y)2 cyclic hexapeptides - Preferred betaturn conformers and implications for beta-turns in proteins, Biochemistry, 20, 4730-4738 (1981).
78. H. Kessler, U. Anders and M. Schudok, An unexpected cis peptide-bond in the minor conformation of a cyclic hexapeptide containing only secondary amide bonds, Journal of the American Chemical Society, 112, 5908-5916 (1990).
79. J. L. Kofron et al., Lithium-chloride perturbation of cis-trans peptide-bond equilibria - Effect on conformational equilibria in cyclosporine A and on timedependent inhibition of cyclophilin, Journal of the American Chemical Society, 114, 2670-2675 (1992).
80. G. Scherer, M. L. Kramer, M. Schutkowski, U. Reimer and G. Fischer, Barriers to rotation of secondary amide peptide bonds, Journal of the American Chemical Society, 120, 5568-5574 (1998).
81. C. Schiene-Fischer and G. Fischer, Direct measurement indicates a slow cis/trans isomerization at the secondary amide peptide bond of glycylglycine, Journal of the American Chemical Society, 123, 6227-6231 (2001).
82. H. Kessler, In: R. H. Sarma, Stereodynamics of Molecular Systems, Pergamon Press, Oxford, New York, Frankfurt, Paris, 1979, 187-196.
83. H. Kessler, P. Kramer and G. Krack, Peptide conformation. 9. Conformational studies on cyclotripeptides containing N-benzyl-glycine, Israel Journal of Chemistry, 20, 188-195 (1980).
84. G. N. Ramachandran, C. Ramakrishnan and V. Sasisekharan, Stereochemistry of polypeptide chain configurations, Journal of Molecular Biology, 7, 95-99 (1963).
85. M. Chorev, Probing the bimolecular interface between RGD-containing ligands and the alpha(v)beta(3) integrin receptor - An important therapeutic target. Part 2, Chimica Oggi, 20, 81-85 (2002).
86. V. Saudek, R. A. Atkinson and J. T. Pelton, 3-dimensional structure of echistatin, the smallest active RGD protein, Biochemistry, 30, 7369-7372 (1991).
87. G. D. Rose, L. M. Gierasch and J. A. Smith, Turns in peptides and proteins, Advances in Protein Chemistry, 37, 1-109 (1985).
88. H. Balaram, K. Uma and P. Balaram, Synthetic peptide models for protein secondary structures. b-sheet formation in acyclic cystine peptides, International Journal of Peptide and Protein Research, 35, 495-500 (1990).
89. C. Bisang et al., Synthesis, conformational properties, and immunogenicity of a cyclic template-bound peptide mimetic containing an NPNA motif from the circumsporozoite protein of plasmodium falciparum, Journal of the American Chemical Society, 120, 7439-7449 (1998).
90. B. Diblasio, A. Lombardi, X. Yang, C. Pedone and V. Pavone, Beta-alanyl-betaalanine in cyclic beta-turned peptides, Biopolymers, 31, 1181-1188 (1991).
91. R. M. Freidinger, Design and synthesis of novel bioactive peptides and peptidomimeties, Journal of Medicinal Chemistry, 46, 5553-5566 (2003).
92. A. Giannis, Peptidomimetics for receptor ligands discovery, development, and medical perspectives, Angewandte Chemie - International Edition, 32, 1244-1267 (1993).
93. E. G. Hutchinson and J. M. Thornton, A revised set of potentials for beta-turn formation in proteins, Protein Science: A Publication of the Protein Society, 3, 2207-2216 (1994).
94. O.Kitagawa et al., Structural-analysis of beta-turn mimics containing a substituted 6-aminocaproic acid linker, Journal of the American Chemical Society, 117, 5169- 5178 (1995).
95. D.F.Mierke,M.Kurz and H.Kessler,Peptide flexibility and calculations of an ensemble of molecules, Journal of the American Chemical Society, 116, 1042-1049 (1994).
96. R. Schwyzer, A. Tunkyi, J. P. Carrion, B. Gorup and H. Nolting, Verdoppelungserscheinungen beim Ringschluss von Peptiden. V. Relative Bedeutung der sterischen Hinclerung and der Assoziation }uber Wasserstoff-Bräcken bei Tripeptiden. Spektroskopische Versuche zur Konformationsbestimmung. 12. Mitteilung }uber homodet cyclische Polypeptide Helvetica Chimica Acta, 47, 441-464 (1964)
97. H. Weisshoff et al., Mimicry of beta II 0-turns of proteins in cyclic pentapeptides with one and without D-amino acids, European Journal of Biochemistry, 259, 776- 788 (1999).
98. J. Chatterjee, D. Mierke and H. Kessler, N-methylated cyclic pentaalanine peptides as template structures, Journal of the American Chemical Society, 128, 15164- 15172 (2006).
99. J. A. Smith and L. G. Pease, Reverse turns in peptides and proteins, CRC Critical Reviews in Biochemistry, 8, 315-399 (1980).
100. C. A. Bewley, H. He, D. H. Williams and D. J. Faulkner, Aciculitins A-C: cytotoxic and antifungal cyclic peptides from the lithistid sponge Aciculites orientalis, Journal of the American Chemical Society, 118, 4314-4321 (1996).
101. K. D. Kopple, On the location of beta-turns, Biopolymers, 20, 1913-1920 (1981).
102. C. Weber et al., The NMR structure of cyclosporine A bound to cyclophilin in aqueous-solution, Biochemistry, 30, 6563-6574 (1991).
103. D. Seebach, A. K. Beck and D. J. Bierbaum, The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components, Chemistry & Biodiversity, 1, 1111-1239 (2004).
104. J. P. Snyder, Probable unimportance of intramolecular hydrogen-bonds for determining the secondary structure of cyclic hexapeptides - Roseotoxin-B, Journal of the American Chemical Society, 106, 2393-2400 (1984).
105. H. Kessler, C. Griesinger and K. Wagner, Peptide conformations. 42. Conformation of side-chains in peptides using heteronuclear coupling-constants obtained by twodimensional NMR-spectroscopy, Journal of the American Chemical Society, 109, 6927-6933 (1987).
106. H. Kessler et al., Does a molecule have the same conformation in the crystalline state and in solution - Comparison of NMR results for the solid-state and solution with those of the X-ray structural determination, Angewandte Chemie - International Edition, 20, 1053-1055 (1981).
107. B. Luy, A. O. Frank and H. Kessler, In: R. Mannhold, Drug Properties: Measurement and Computation, 2008, 207-254.
108. M. Heller et al., The conformation of cyclo(-D-Pro-Ala(4)-) as a model for cyclic pentapeptides of the DL4 type, Journal of the American Chemical Society, 128, 13806-13814 (2006).
109. W. Liu et al., Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices, Biochemistry, 44, 3591-3597 (2005).
110. A. Senes, D. E. Engel and W. F. DeGrado, Folding of helical membrane proteins: the role of polar, GxxxG-like and proline motifs, Current Opinion in Structural Biology, 14, 465-479 (2004).
111. H. Matter and H. Kessler, Structures, dynamics, and biological-activities of 15 cyclic hexapeptide analogs of the alpha-amylase inhibitor tendamistat (HOE- 467) in solution, Journal of the American Chemical Society, 117, 3347-3359 (1995).
112. Y. B. He, Z. W. Huang, K. Raynor, T. Reisine and M. Goodman, Syntheses and conformations of somatostatin-related cyclic hexapeptides incorporating specific alpha-methylated and beta-methylated residues, Journal of the American Chemical Society, 115, 8066-8072 (1993).
113. J. D. Dunitz and J. Waser, Geometric constraints in 6-membered and 8-membered rings, Journal of the American Chemical Society, 94, 5645-5650 (1972).
114. Y. A. Bara et al., Synthesis of cyclic pentapeptides containing L-phenylalanine and glycine, Chemische Berichte-Recueil, 111, 1029-1044 (1978).
115. J. Dale and K. Titlestad, Conformational processes in simple cyclic peptides, Acta Chemica Scandinavica Series B - Organic Chemistry and Biochemistry, B 29, 353-361 (1975).
116. M. Gurrath, G. Mü ller, H. Kessler, M. Aumailley and R. Timpl, Conformation activity studies of rationally designed potent antiadhesive RGD peptides, European Journal of Biochemistry, 210, 911-921 (1992).
117. H. Kessler and B. Kutscher, Synthesis andNMRinvestigation of cyclic pentapeptide analogs of thymopentin, Tetrahedron Letters, 26, 177-180 (1985).
118. H. Kessler et al., Design, synthesis, and conformation of superacitve thymopoietinanalogs, Pept Struct Funct Proc Am Pept Symp 9th, 83-92 (1985).
119. H. Kessler, B. Kutscher and A. Klein, Peptide conformations. 39. NMR-studies of the conformation of cyclic pentapeptide analogs of thymopoietin, Liebigs Annalen der Chemie, 893-913 (1986).
120. H. Kessler and B. Kutscher, Peptide conformations. 40. Cyclic hexapeptide analogs of thymopoietin - Synthesis and conformational-analysis, Liebigs Annalen der Chemie, 914-931 (1986).
121. H. Kessler, R. Gratias, G. Hessler, M. Gurrath and G. Muller, Conformation of cyclic peptides. Principle concepts and the design of selectivity and superactivity in bioactive sequences by 'spatial screening', Pure and Applied Chemistry, 68, 1201- 1205 (1996).
122. V. Duvigneaud, G. S. Denning, W. Y. Chan and S. Drabarek, Synthesis and pharmacological study of 4-decarboxamido-oxytocin (4-alpha-aminobutyric acidoxytocin) and 5-decarboxamido-oxytocin (5-alanine-oxytocin), Journal of Biological Chemistry, 239, 472-478 (1964).
123. S. Rothemund et al., Structure effects of double D-amino-acid replacements - A nuclear-magnetic-resonance and circular-dichroism study using amphipathic model helices, Biochemistry, 34, 12954-12962 (1995).
124. K. Palczewski et al., Crystal structure of rhodopsin: A G protein-coupled receptor, Science, 289, 739-745 (2000).
125. S. G. F. Rasmussen et al., Crystal structure of the human beta(2) adrenergic G-protein-coupled receptor, Nature, 450, 383-387 (2007).
126. T. Warne et al., structure of a b (1)-adrenergic G-protein-coupled receptor, Nature, 454, 486-491 (2008).
127. V. Jaakola et al., The 2.6 A° Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist, science, 322, 1211-1217 (2008).
128. J. A. Elbe and K. Kü hn, Integrin-Ligand Interaction, Springer, Heidelberg, 1997.
129. K. J. Clemetson and J. M. Clemetson, Integrins and cardiovascular disease, Cellular and Molecular Life Sciences, 54, 502-513 (1998).
130. H. Jin and J. Varner, Integrins: roles in cancer development and as treatment targets, British Journal of Cancer, 90, 561-565 (2004).
131. A. J. Rojas and A. R. Ahmed, Adhesion receptors in health and disease, Critical Reviews in Oral Biology and Medicine, 10, 337-358 (1999).
132. H. Yusuf-Makagiansar, M. E. Anderson, T. V. Yakovleva, J. S. Murray and T. J. Siahaan, Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune disease, Medicinal Research Reviews, 22, 146-167 (2002).
133. M. D. Pierschbacher and E. Ruoslahti, Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule, Nature, 309, 30-33 (1984).
134. L.Tranqui et al.,Differential structural requirementsfor fibrinogenbindingtoplatelets and to endothelial cells, The Journal of Cell Biology, 108, 2519-2527 (1989).
135. M. Pfaff, et al., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins, The Journal of Biological Chemistry, 269, 20233-20238 (1994).
136. G. Mü ller, M. Gurrath and H. Kessler, Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides, Journal of Computer-Aided Molecular Design, 8, 709-730 (1994).
137. J. Wermuth, S. L. Goodman, A. Jonczyk and H. Kessler, Stereoisomerism and biological activity of the selective and superactive alpha(v)beta(3) integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide, Journal of the American Chemical Society, 119, 1328-1335 (1997).
138. M. A. Dechantsreiter et al., N-methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists, Journal of Medicinal Chemistry, 42, 3033-3040 (1999).
139. D. Finsinger, In: Institut fü r Organische Chemie und Biochemie, Technische Universitä tMü nchen, Mü nchen, 1997, 161.
140. F. Schumann, A. Mü ller, M. Koksch, G. Mü ller and N. Sewald, Are beta-amino acids gamma-turn mimetics? Exploring a new design principle for bioactive cyclopeptides, Journal of the American Chemical Society, 122, 12009-12010 (2000).
141. D. Zimmermann, et al., Integrin alpha(5)beta(1) ligands: Biological evaluation and conformational analysis, ChemBioChem, 6, 272-276 (2005).
142. S. A. W. Gruner, E. Locardi, E. Lohof and H. Kessler, Carbohydrate-based mimetics in drug design: sugar amino acids and carbohydrate scaffolds, Chemical Reviews, 102, 491-514 (2002).
143. E. von Roedern and H. Kessler, A sugar amino-acid as a novel peptidomimetic, Angewandte Chemie - International Edition, 33, 687-689 (1994).
144. E. von Roedern, E. Lohof, G. Hessler, M. Hoffmann and H. Kessler, Synthesis and conformational analysis of linear and cyclic peptides containing sugar amino acids, Journal of the American Chemical Society, 118, 10156-10167 (1996).
145. S. Cheng et al., Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha(IIb)beta(3) antagonists, Journal of Medicinal Chemistry, 37, 1-8 (1994).
146. K. D. Kopple et al., Conformations of Arg-Gly-Asp containing heterodetic cyclicpeptides - Solution and crystal studies, Journal of the American Chemical Society, 114, 9615-9623 (1992).
147. R. M. Scarborough and D. D. Gretler, Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: Novel parenteral and potential oral antithrombotic agents, Journal of Medicinal Chemistry, 43, 3453-3473 (2000).
148. J. Samanen et al., Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro, Journal of Medicinal Chemistry, 34, 3114-3125 (1991).
149. F. E. Ali et al., Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and plateletaggregation, Journal of Medicinal Chemistry, 37, 769-780 (1994).
150. M. Burger et al., Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells, Blood, 106, 1824-1830 (2005).
151. C. Murdoch, CXCR4: Chemokine receptor extraordinaire, Immunological Reviews, 177, 175-184 (2000).
152. K. Kanbara et al., Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134, AIDS Research and Human Retroviruses, 17, 615-622 (2001).
153. T. Nanki et al., Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4(+) T cell accumulation in rheumatoid arthritis synovium, Journal of Immunology ,165, 6590-6598 (2000).
154. H. Tamamura et al., Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent, FEBS Letters, 569, 99-104 (2004).
155. M. Takenaga et al., A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma, Biochemical and Biophysical Research Communications, 320, 226-232 (2004).
156. H. Tamamura et al., T140 analogs as CXCR4 antagonists identified as anti- metastatic agents in the treatment of breast cancer, FEBS Letters, 550, 79-83 (2003).
157. T. Nakamura et al., Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe-crab (tachypleus-tridentatus) - Isolation and chemical- structure, Journal of Biological Chemistry, 263, 16709-16713 (1988).
158. T. Miyata, et al., Antimicrobial peptides, isolated from horseshoe-crab hemocytes, tachyplesin-Il, and polyphemusin-I and polyphemusin-II - Chemical structures and biological-activity, Journal of Biochemistry, 106, 663-668 (1989).
159. M. Morimoto et al., Inhibitory effect of tachyplesin-I on the proliferation of humanimmunodeficiency- virus in vitro, Chemotherapy, 37, 206-211 (1991).
160. T. Murakami, M. Niwa, F. Tokunaga, T. Miyata and S. Iwanaga, Direct virus inactivation of tachyplesin-I and its isopeptides from horseshoe-crab hemocytes, Chemotherapy, 37, 327-334 (1991).
161. K. Kawano et al., Antimicrobial peptide, tachyplesin-I, isolated from hemocytes of the horseshoe-crab (tachypleus-tridentatus) - NMR determination of the beta-sheet structure, Journal of Biological Chemistry, 265, 15365-15367 (1990).
162. M. Masuda et al., A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]- Polyphemusin-II), Biochemical and Biophysical Research Communications, 189, 845-850 (1992).
163. H. Tamamura et al., Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure, Bioorganic & Medicinal Chemistry, 6, 473-479 (1998).
164. H. Tamamura et al., A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140, Biochemical and Biophysical Research Communications, 253, 877-882 (1998).
165. H. Tamamura et al., Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II), Bioorganic & Medicinal Chemistry, 6, 231-238 (1998).
166. H. Tamamura et al., Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes, Bioorganic & Medicinal Chemistry Letters, 10, 2633-2637 (2000).
167. N. Fujii et al., Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries, Angewandte Chemie - International Edition, 42, 3251-3253 (2003).
168. S. Ueda et al., Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: Disclosing the importance of side-chain and backbone functionalities, Journal of Medicinal Chemistry, 50, 192-198 (2007).
169. G. Weckbecker et al., Opportunities in somatostatin research: Biological, chemical and therapeutic aspects, Nature Reviews Drug Discovery, 2, 999-1017 (2003).
170. C. E. DiLiberti, The best targets for biogenerics, BioPharm International, 19, 50-52, 54, 56, 58, 60, 62, 64 (2006).
171. D. F. Veber, et al., A potent cyclic hexapeptide analog of somatostatin, Nature, 292, 55-58 (1981).